MVA-BN- HER2 vaccine: Phase I/II data

Data from a Phase I/II trial showed that MVA-BN-HER2 vaccine generated an immune response against epidermal growth factor (EGF) receptor 2 (HER2, ErbB2, neu) in about 70% of about 25 evaluable patie...